| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Ensitrelvir fumarate (S-217622 fumarate; Xocova) is a novel and orally bioavailable SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) approval in Japan under the emergency regulatory approval system (EUA) for COVID-19 treatment. It is an antiviral drug developed by Shionogi in partnership with Hokkaido University. It became the first Japanese domestic pill to treat COVID-19, third to be regulatorally approved in Japan; in February 2022.
| ln Vitro |
|
|
|---|---|---|
| ln Vivo |
|
|
| References |
|
| Molecular Formula |
C26H21CLF3N9O6
|
|---|---|
| Molecular Weight |
647.9562
|
| Elemental Analysis |
C, 48.20; H, 3.27; Cl, 5.47; F, 8.80; N, 19.46; O, 14.81
|
| CAS # |
2757470-18-9
|
| Related CAS # |
2647530-73-0;2757470-18-9 (fumarate);
|
| Appearance |
Solid powder
|
| SMILES |
O=C(N(CC1=NN(C)C=N1)C(N/2)=O)N(CC3=CC(F)=C(F)C=C3F)C2=N\C4=CC5=CN(C)N=C5C=C4Cl.O=C(O)/C=C/C(O)=O
|
| InChi Key |
FBOCUALVLIWPNQ-WLHGVMLRSA-N
|
| InChi Code |
InChI=1S/C22H17ClF3N9O2.C4H4O4/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)245-3(6)1-2-4(7)8/h3-7,10H,8-9H2,1-2H3,(H,28,29,36)1-2H,(H,5,6)(H,7,8)/b2-1+
|
| Chemical Name |
(E)-6-((6-chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione fumaric acid
|
| Synonyms |
S 217622; S217622; Xocova;S-217622
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~77.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.86 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5433 mL | 7.7165 mL | 15.4331 mL | |
| 5 mM | 0.3087 mL | 1.5433 mL | 3.0866 mL | |
| 10 mM | 0.1543 mL | 0.7717 mL | 1.5433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
